Literature DB >> 17984697

Advanced pediatric inoperable thymus carcinoma (type C thymoma): case report on a novel therapeutic approach.

Gabriella P Kertesz1, Peter Hauser, Peter Varga, Gabriella Dabasi, Dezso Schuler, Miklos Garami.   

Abstract

Although there has been considerable advancement in treatment techniques but still there are some illnesses that continue to exhibit a rather poor curability, such as thymoma. This report highlights the benefit of octreotide and prednisolone therapy in a 15-year-old girl, who was diagnosed with inoperable thymus carcinoma, with chemotherapy and radiotherapy being the last resort. The detection of type 2 somatostatin receptors on the surface of the tumor justified the introduction of treatment with somatostatin analog and prednisolone. Fortunately, after 6 months of this treatment, the tumor showed partial regression. However, 2 months later, somatostatin receptor negative metastases appeared; therefore, a switch over to imatinib became essential, because the tumor was CD-117 positive. Despite the therapy change, the patient's condition deteriorated owing to tumor progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984697     DOI: 10.1097/MPH.0b013e318159a535

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.

Authors:  P Ströbel; R Bargou; A Wolff; D Spitzer; C Manegold; A Dimitrakopoulou-Strauss; L Strauss; C Sauer; F Mayer; P Hohenberger; A Marx
Journal:  Br J Cancer       Date:  2010-06-22       Impact factor: 7.640

Review 2.  The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

Authors:  Liliana Montella; Margaret Ottaviano; Rocco Morra; Erica Pietroluongo; Pietro De Placido; Marianna Tortora; Chiara Sorrentino; Gaetano Facchini; Sabino De Placido; Mario Giuliano; Giovannella Palmieri
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639

3.  A review of the use of somatostatin analogs in oncology.

Authors:  Ozge Keskin; Suayib Yalcin
Journal:  Onco Targets Ther       Date:  2013-04-26       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.